MX2023011733A - Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin. - Google Patents
Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin.Info
- Publication number
- MX2023011733A MX2023011733A MX2023011733A MX2023011733A MX2023011733A MX 2023011733 A MX2023011733 A MX 2023011733A MX 2023011733 A MX2023011733 A MX 2023011733A MX 2023011733 A MX2023011733 A MX 2023011733A MX 2023011733 A MX2023011733 A MX 2023011733A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- small cell
- cell lung
- lung carcinoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171536P | 2021-04-06 | 2021-04-06 | |
| US202163171571P | 2021-04-06 | 2021-04-06 | |
| PCT/US2022/023629 WO2022216796A1 (en) | 2021-04-06 | 2022-04-06 | Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011733A true MX2023011733A (es) | 2023-10-13 |
Family
ID=83510391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011733A MX2023011733A (es) | 2021-04-06 | 2022-04-06 | Metodos para el tratamiento del carcinoma de pulmon de celulas no peque?as usando telisotuzumab vedotin. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12433951B2 (https=) |
| EP (1) | EP4319811A1 (https=) |
| JP (1) | JP2024514506A (https=) |
| BR (1) | BR112023020562A2 (https=) |
| CA (1) | CA3214989A1 (https=) |
| MX (1) | MX2023011733A (https=) |
| WO (1) | WO2022216796A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024243450A1 (en) * | 2023-05-23 | 2024-11-28 | Abbvie Inc. | Methods of treatment using anti-c-met antibody drug conjugates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| EP2402370A1 (en) | 2010-06-29 | 2012-01-04 | Pierre Fabre Médicament | Novel antibody for the diagnosis and/or prognosis of cancer |
| EP3448427A1 (en) * | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
| SI3626273T1 (sl) | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
| WO2020065396A1 (en) | 2018-09-26 | 2020-04-02 | Genmab A/S | Axl-specific antibodies for treatment of non-small cell lung cancer |
| US20210107969A1 (en) * | 2019-07-09 | 2021-04-15 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
-
2022
- 2022-04-06 BR BR112023020562A patent/BR112023020562A2/pt unknown
- 2022-04-06 US US17/714,724 patent/US12433951B2/en active Active
- 2022-04-06 CA CA3214989A patent/CA3214989A1/en active Pending
- 2022-04-06 WO PCT/US2022/023629 patent/WO2022216796A1/en not_active Ceased
- 2022-04-06 JP JP2023560513A patent/JP2024514506A/ja active Pending
- 2022-04-06 MX MX2023011733A patent/MX2023011733A/es unknown
- 2022-04-06 EP EP22785354.6A patent/EP4319811A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022253888A9 (en) | 2024-02-22 |
| CA3214989A1 (en) | 2022-10-13 |
| US12433951B2 (en) | 2025-10-07 |
| EP4319811A1 (en) | 2024-02-14 |
| AU2022253888A1 (en) | 2023-09-28 |
| WO2022216796A1 (en) | 2022-10-13 |
| JP2024514506A (ja) | 2024-04-02 |
| BR112023020562A2 (pt) | 2023-12-05 |
| US20220323597A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004656A (es) | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. | |
| CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| CO2019008783A2 (es) | Compuestos dinucleotidos ciclicos para el tratamiento del cancer | |
| MX2020012204A (es) | Inhibidores de kras g12c para tratar el cáncer. | |
| MX2021007927A (es) | Metodos para tratar trastornos usando inhibidores de csf1r. | |
| MX2025002382A (es) | Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer | |
| ECSP17073743A (es) | Moduladores de k-ras | |
| MX391470B (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| EA201890730A1 (ru) | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| MX344355B (es) | Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| NI201400095A (es) | Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa. | |
| MX375716B (es) | Método para tratar adenocarcinoma de pulmón. | |
| AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| MX2016002051A (es) | Metodos y kits para la subtipificacion molecular de tumores. | |
| BR112018009753A8 (pt) | bactérias de virulência atenuada para o tratamento de tumores sólidos malignos | |
| MX391999B (es) | Piridinas y su uso en el tratamiento del cáncer. | |
| MX2019009356A (es) | Sulfinilpiridinas y su uso en el tratamiento del cancer. | |
| MX2023002104A (es) | Composiciones y métodos para tratar cánceres positivos para egfr. | |
| EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
| AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
| MX2023007918A (es) | Uso de un inhibidor de kras g12c en el tratamiento de canceres. | |
| MX2020002053A (es) | [6r]-mthf - una alternativa eficaz al folato en quimioterapia basada en 5-fluorouracilo. |